Ann Lee-Karlon will build the company’s pipeline of bispecific antibody protein degrader therapeutics. Photo: EpiBiologics / Business Wire.

Biotechnology company EpiBiologics has appointed Dr Ann Lee-Karlon as CEO, president and a member of its board. 

Lee-Karlon will handle activities related to the expansion of the EpiTAC platform, a modular antibody-based system. She will establish partnerships and create a bispecific antibody protein degrader therapeutics pipeline. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Lee-Karlon previously worked as chief operating officer at Altos Labs. She has also served as senior vice-president at Genentech.

Lee-Karlon stated: “EpiBiologics has developed a groundbreaking platform to target membrane and extracellular proteins, leveraging a novel atlas of tissue-specific degrader antibodies. 

“Targeted extracellular protein degradation represents a new therapeutic modality with a wide range of applications, including cancer, immunology and neurological diseases.”

EpiBiologics has also raised $23m in a new Series A financing round, taking the total Series A funds to $73m.

New investors Digitalis Ventures and Taiho Ventures and current investor Codon Capital provided the latest financing.

EpiBiologics was launched in March 2023 with Series A financing of $50m from investors Polaris Partners, Mubadala Capital, Vivo Capital and GV. 

The EpiTAC platform aids in the tissue-specific breakdown of disease-causing membrane and extracellular proteins.

Digitalis Ventures partner Samuel Bjork stated: “EpiBiologics has made tremendous progress with its leading-edge EpiTAC platform, which will unravel the underlying intricacies of disease biology to build precision therapeutics.”